Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany

Annals of Hematology

Volumn 91, Issue 2, 2012, Pages 243-248

  Eisele, Lewin ^a   Dürig, Jan ^a   Hüttmann, Andreas ^a   Dührsen, Ulrich ^a   Assert, Roland ^a   Bokhof, Beate ^a   Erbel, Raimund ^a   Mann, Klaus ^a   Jöckel, Karl Heinz ^a   Moebus, Susanne ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Germany; LCMGUS; MGUS; Population based; Prevalence

Indexed keywords

C REACTIVE PROTEIN; CREATININE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN BICLONAL CHAIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; M PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; ELECTROPHORESIS; FEMALE; GERMANY; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOASSAY; IMMUNOFIXATION; IMMUNOPATHOGENESIS; KIDNEY DISEASE; LIGHT CHAIN MONOCLONAL IMMUNOGLOBULINEMIA; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS;

AGED; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MYELOMA PROTEINS;

EID: 84857356585     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1293-1     Document Type: Article

References (17)

1. International Myeloma Working Group 2003 Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group Br J Haematol 121 5 749 757 10.1046/j.1365-2141.2003.04355.x (Pubitemid 36718191)
2. RA Kyle TM Therneau SV Rajkumar DR Larson MF Plevak JR Offord A Dispenzieri JA Katzmann LJ Melton 3rd 2006 Prevalence of monoclonal gammopathy of undetermined significance N Engl J Med 354 13 1362 1369 10.1056/NEJMoa054494 16571879 10.1056/NEJMoa054494 1:CAS:528:DC%2BD28XjtVCisr4%3D
3. J Blade L Rosinol MT Cibeira CF de Larrea 2008 Pathogenesis and progression of monoclonal gammopathy of undetermined significance Leukemia 22 1651 1657 10.1038/leu.2008.203 18668131 10.1038/leu.2008.203 1:CAS:528:DC%2BD1cXhtVyqu73I
4. RA Kyle TM Therneau SV Rajkumar JR Offord DR Larson MF Plevak LJ Melton 3rd 2002 A long-term study of prognosis in monoclonal gammopathy of undetermined significance N Engl J Med 346 8 564 569 10.1056/NEJMoa01133202 11856795 10.1056/NEJMoa01133202 (Pubitemid 34438817)
5. O Landgren RA Kyle RM Pfeiffer JA Katzmann NE Caporaso RB Hayes A Dispenzieri S Kumar RJ Clark D Baris R Hoover SV Rajkumar 2009 Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Blood 113 22 5412 5417 10.1182/blood-2008-12-194241 19179464 10.1182/blood-2008-12-194241 1:CAS:528:DC%2BD1MXntVertLY%3D
6. BM Weiss J Abadie P Verma RS Howard WM Kuehl 2009 A monoclonal gammopathy precedes multiple myeloma in most patients Blood 113 22 5418 5422 10.1182/blood-2008-12-195008 19234139 10.1182/blood-2008-12-195008 1:CAS:528:DC%2BD1MXntVertLc%3D
7. A Dispenzieri JA Katzmann RA Kyle DR Larson LJ Melton 3rd CL Colby TM Therneau R Clark SK Kumar A Bradwell R Fonseca DF Jelinek SV Rajkumar 2010 Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study Lancet 375 9727 1721 1728 10.1016/S0140-6736(10)60482-5 20472173 10.1016/S0140-6736(10) 60482-5
8. A Schmermund S Möhlenkamp A Stang D Grönemeyer R Seibel H Hirche K Mann W Siffert K Lauterbach J Siegrist KH Jöckel R Erbel 2002 Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle Am Heart J 144 2 212 218 12177636 10.1067/mhj.2002.123579 (Pubitemid 34879641)
9. A Stang S Moebus N Dragano EM Beck S Möhlenkamp A Schmermund J Siegrist R Erbel KH Jöckel 2005 Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: identifiability of phone numbers as the major determinant of response Eur J Epidemiol 20 6 489 496 16121757 10.1007/s10654-005-5529-z 1:STN:280:DC%2BD2MvlsVOksA%3D%3D (Pubitemid 40933925)
10. JA Katzmann RJ Clark RS Abraham S Bryant JF Lymp AR Bradwell RA Kyle 2002 Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains Clin Chem 48 9 1437 1444 12194920 1:CAS:528:DC%2BD38XmslSqtbo%3D (Pubitemid 34925779)
11. JR Tate D Gill R Cobcroft PE Hickman 2003 Practical considerations for the measurement of free light chains in serum Clin Chem 49 8 1252 1257 12881439 10.1373/49.8.1252 1:CAS:528:DC%2BD3sXlvF2nsbk%3D (Pubitemid 36900609)
12. RN Anderson HM Rosenberg 1998 Age standardization of death rates: implementation of the year 2000 standard Natl Vital Stat Rep 47 3 1 16 1:STN:280:DyaK1M%2Fht1eguw%3D%3D 20
13. SV Rajkumar RA Kyle TM Therneau LJ Melton 3rd AR Bradwell RJ Clark DR Larson MF Plevak A Dispenzieri JA Katzmann 2005 Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance Blood 106 3 812 817 10.1182/blood-2005-03-1038 15855274 10.1182/blood-2005-03-1038 1:CAS:528:DC%2BD2MXntVSntbo%3D (Pubitemid 41076419)
14. PG Hill JM Forsyth B Rai S Mayne 2006 Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies Clin Chem 52 9 1743 1748 10.1373/clinchem.2006.069104 16858075 10.1373/clinchem.2006.069104 1:CAS:528:DC%2BD28Xpt1Wit74%3D (Pubitemid 44330709)
15. CA Hutchison K Basnayake P Cockwell 2009 Serum free light chain assessment in monoclonal gammopathy and kidney disease Nat Rev Nephrol 5 11 621 628 10.1038/nrneph.2009.151 19786994 10.1038/nrneph.2009.151 1:CAS:528:DC%2BD1MXhtlWhur%2FK
16. GR Bailie K Uhlig AS Levey 2005 Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease Pharmacotherapy 25 4 491 502 15977910 10.1592/phco.25.4.491.61034 (Pubitemid 40471492)
17. JA Katzmann RA Kyle J Benson DR Larson MR Snyder JA Lust SV Rajkumar A Dispenzieri 2009 Screening panels for detection of monoclonal gammopathies Clin Chem 55 8 1517 1522 10.1373/clinchem.2009.126664 19520758 10.1373/clinchem.2009. 126664 1:CAS:528:DC%2BD1MXptleis7c%3D